Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P08908
UPID:
5HT1A_HUMAN
Alternative names:
G-21; Serotonin receptor 1A
Alternative UPACC:
P08908; Q6LAE7
Background:
The 5-hydroxytryptamine receptor 1A, also known as G-21 or Serotonin receptor 1A, is a pivotal G-protein coupled receptor. It binds to serotonin and various psychoactive substances, initiating a cascade of signaling events. This receptor plays a crucial role in modulating neural activity, mood, and behavior by regulating serotonin and dopamine levels in the brain.
Therapeutic significance:
Periodic fever, menstrual cycle-dependent, is linked to variants affecting this gene. Understanding the role of 5-hydroxytryptamine receptor 1A could open doors to potential therapeutic strategies for managing this condition and its associated symptoms.